TNF Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details Narrative) - Pro Forma [Member] - shares	Apr. 16, 2021	Sep. 11, 2020
Subsequent Event [Member]
Merger agreement, description	Among other things, the A&R Charter (i) changed the Company's name to MyMD Pharmaceuticals, Inc., (ii) increased the number of shares of Company Common Stock available from 100,000,000 shares to a total of 500,000,000 shares of the Company's Common Stock, (iii) changed the structure of the board of directors from a classified board of three classes to a non-classified board of a single class, and (iv) simplified and consolidated various provisions.
2018 Stock Incentive Plan [Member] \| Restricted Stock [Member]
Stock options issued during period		394,680
2021 Stock Incentive Plan [Member] \| Subsequent Event [Member]
Common stock reserved for future issuance	7,228,184